



### CME Session 1

Oncology and Theranostics Committee

Sunday, October 18, 08:00–09:30

### Session Title

**The Alpha Era in Prostate Cancer: Progress, Challenges, and Next Steps**

### Chairpersons

**Karolien Goffin** (Leuven, Belgium)

**Matteo Bauckneht** (Genova, Italy)

### Programme

- 08:00–08:20 **Andreas Kjaer** (Copenhagen, Denmark): What are the most Promising Alpha-Emitters?
- 08:20–08:45 **Matthias Eiber** (Munich, Germany): Why is TAT Relevant for Prostate Cancer?
- 08:45–09:10 **Louise Emmett** (Sydney, Australia): How to Properly Select and Monitor Patients Treated with TAT?
- 09:10–09:30 **Tessa Brabander** (Rotterdam, Netherlands): TAT-Challenges and Future Directions

### Educational Objectives

1. To become familiar with the most promising Alpha-emitters
2. To understand the mechanism of action of TAT and the clinical relevancy for prostate cancer
3. To learn how to properly select and monitor patients treated with TAT

### Summary

Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumours. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. In this session the most interesting Alpha-emitters to be used in clinical practice will be discussed. The relevance for the implementation of TAT in patients with prostate cancer will be underlined. Since the adoption of TAT requires a good knowledge of the Alpha-emitters properties, the proper selection and monitoring of the patients treated with TAT will be explained.

### Key Words

Alpha Emitters, Targeted Alpha Therapy (TAT), Response Monitoring, Patient Selection, Prostate Cancer